North China Pharmaceutical Co Ltd Financial Flexibility Index
North China Pharmaceutical Co Ltd financial flexibility index. North China Pharmaceutical Co Ltd (600812) has a Financial Flexibility Index of 0.02x as of September 2025. Free cash flow of CN¥314.62 Million (operating CF CN¥170.24 Million minus capex CN¥144.38 Million) represents 0% of total liabilities (CN¥14.86 Billion). Explore 600812 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of North China Pharmaceutical Co Ltd (1998–2025)
Financial flexibility index of North China Pharmaceutical Co Ltd from 1998 to 2025. Historical Financial Flexibility Index trend for North China Pharmaceutical Co Ltd across 28 annual periods. Check North China Pharmaceutical Co Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
North China Pharmaceutical Co Ltd Financial Flexibility Index by Year (1998–2025)
North China Pharmaceutical Co Ltd financial flexibility index by year from 1998 to 2025. Year-by-year free cash flow to debt coverage for North China Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see North China Pharmaceutical Co Ltd cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.12x | CN¥1.72 Billion | CN¥1.18 Billion | CN¥14.51 Billion | ▼ -13.0% |
| 2024 | 0.14x | CN¥2.01 Billion | CN¥1.23 Billion | CN¥14.80 Billion | ▲ +21.3% |
| 2023 | 0.11x | CN¥1.65 Billion | CN¥1.02 Billion | CN¥14.69 Billion | ▲ +8.2% |
| 2022 | 0.10x | CN¥1.55 Billion | CN¥1.00 Billion | CN¥14.99 Billion | ▲ +16.2% |
| 2021 | 0.09x | CN¥1.60 Billion | CN¥1.05 Billion | CN¥17.91 Billion | ▼ -14.4% |
| 2020 | 0.10x | CN¥1.76 Billion | CN¥752.15 Million | CN¥16.88 Billion | ▼ -2.4% |
| 2019 | 0.11x | CN¥1.38 Billion | CN¥732.97 Million | CN¥12.92 Billion | ▲ +3.4% |
| 2018 | 0.10x | CN¥1.28 Billion | CN¥774.33 Million | CN¥12.40 Billion | ▲ +78.4% |
| 2017 | 0.06x | CN¥686.94 Million | CN¥287.25 Million | CN¥11.87 Billion | ▲ +509.8% |
| 2016 | -0.01x | CN¥-157.93 Million | CN¥-446.53 Million | CN¥11.18 Billion | ▼ -130.9% |
| 2015 | 0.05x | CN¥490.31 Million | CN¥122.50 Million | CN¥10.73 Billion | ▲ +35.2% |
| 2014 | 0.03x | CN¥348.86 Million | CN¥90.56 Million | CN¥10.32 Billion | ▼ -17.3% |
| 2013 | 0.04x | CN¥425.92 Million | CN¥-135.03 Million | CN¥10.41 Billion | ▼ -61.7% |
| 2012 | 0.11x | CN¥1.00 Billion | CN¥-63.92 Million | CN¥9.36 Billion | ▼ -22.1% |
| 2011 | 0.14x | CN¥1.36 Billion | CN¥227.60 Million | CN¥9.95 Billion | ▲ +94.9% |
| 2010 | 0.07x | CN¥558.27 Million | CN¥-598.35 Million | CN¥7.94 Billion | ▼ -67.3% |
| 2009 | 0.21x | CN¥1.38 Billion | CN¥1.01 Billion | CN¥6.41 Billion | ▼ -5.8% |
| 2008 | 0.23x | CN¥1.22 Billion | CN¥1.09 Billion | CN¥5.37 Billion | ▲ +55.9% |
| 2007 | 0.15x | CN¥762.64 Million | CN¥664.37 Million | CN¥5.22 Billion | ▲ +26.5% |
| 2006 | 0.12x | CN¥648.84 Million | CN¥597.12 Million | CN¥5.61 Billion | ▲ +56.8% |
| 2005 | 0.07x | CN¥408.84 Million | CN¥224.17 Million | CN¥5.55 Billion | ▼ -34.1% |
| 2004 | 0.11x | CN¥658.89 Million | CN¥310.39 Million | CN¥5.89 Billion | ▼ -50.7% |
| 2003 | 0.23x | CN¥1.02 Billion | CN¥580.32 Million | CN¥4.51 Billion | ▲ +1.1% |
| 2002 | 0.22x | CN¥963.19 Million | CN¥738.50 Million | CN¥4.29 Billion | ▲ +86.1% |
| 2001 | 0.12x | CN¥559.07 Million | CN¥367.28 Million | CN¥4.63 Billion | ▲ +70.6% |
| 2000 | 0.07x | CN¥231.00 Million | CN¥133.49 Million | CN¥3.27 Billion | ▲ +171.7% |
| 1999 | -0.10x | CN¥-285.87 Million | CN¥-373.62 Million | CN¥2.90 Billion | ▲ +32.3% |
| 1998 | -0.15x | CN¥-292.55 Million | CN¥-326.74 Million | CN¥2.01 Billion | — |